Jackson Creek Investment Advisors LLC Purchases New Shares in GeneDx Holdings Corp. (NASDAQ:WGS)

Jackson Creek Investment Advisors LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 15,560 shares of the company’s stock, valued at approximately $1,378,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in shares of GeneDx by 26.6% during the 4th quarter. Bank of New York Mellon Corp now owns 40,914 shares of the company’s stock worth $3,145,000 after purchasing an additional 8,597 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in GeneDx by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 151,403 shares of the company’s stock worth $11,637,000 after purchasing an additional 4,369 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of GeneDx in the 4th quarter worth approximately $209,000. Swiss National Bank boosted its position in GeneDx by 16.7% during the 4th quarter. Swiss National Bank now owns 23,800 shares of the company’s stock worth $1,829,000 after acquiring an additional 3,400 shares during the period. Finally, Royce & Associates LP raised its stake in shares of GeneDx by 11.6% in the 4th quarter. Royce & Associates LP now owns 31,567 shares of the company’s stock worth $2,426,000 after buying an additional 3,274 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 9,657 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total value of $878,207.58. Following the transaction, the chief executive officer directly owned 4,940 shares in the company, valued at approximately $449,243.60. This trade represents a 66.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 5,278 shares of the firm’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the transaction, the chief financial officer owned 3,392 shares in the company, valued at $315,456. This represents a 60.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,411 shares of company stock worth $2,104,828. Insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, July 13th. TD Securities cut their target price on GeneDx from $135.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Jefferies Financial Group raised GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Friday, May 9th. Finally, Wells Fargo & Company dropped their price target on GeneDx from $105.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $92.33.

GeneDx Stock Performance

GeneDx stock traded down $0.23 during trading hours on Friday, hitting $80.19. The stock had a trading volume of 20,228 shares, compared to its average volume of 825,404. GeneDx Holdings Corp. has a fifty-two week low of $25.32 and a fifty-two week high of $117.75. The company has a quick ratio of 3.07, a current ratio of 3.25 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average of $75.12 and a two-hundred day moving average of $82.78. The company has a market cap of $2.29 billion, a PE ratio of -57.29 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last issued its earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. The business had revenue of $87.12 million during the quarter, compared to analysts’ expectations of $79.90 million. GeneDx had a positive return on equity of 10.17% and a negative net margin of 11.69%. On average, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.